AbbVie

AbbVie is a public biopharmaceutical company that started as a spinoff of Abbott Laboratories. They work on creating innovative approaches to many of the life-threatening or chronic conditions that people experience today including diseases that have proven very difficult to cure. They have a very large research and development division and have come up with some of the most recognizable and innovative medicines on the market today. Their headquarters are in Lake Bluff, Illinois, and they employ over 28,000 people. Many of those positions include scientists, researchers, manufacturing specialists, regulatory experts, communicators, administrators and managers. However, they also have employment opportunities in marketing, human resources, accounting, and many other departments.

Abbott Laboratories announced in 2011 that they were going to separate into two different publicly traded companies. One company would keep the name Abbott Laboratories and would specialize in products like medical devices, nutrition products, and diagnostic equipment, while AbbVie would remain in the pharmaceutical field and continue to research medications. The spinoff happen on January 1, 2013, and the company went public the very next day. Some of the best-known products that AbbVie has created include the following:

* Humira (adalimumab)

* Imbruvica (ibrutinib)

* Venclexta (venetoclax)

* Zinbryta (daclizumab)

* Kaletra (lopinavir)

* Norvir (ritonavir)

* Mavyret/Maviret (glecaprevir/pibrentasvir)
Although this company is based primarily in the United States and does most of their business there with research labs and operation centers in North America, as of 2015, they employed more than 28,000 people across the globe in various locations. When it comes to product reach, the scope is even wider with products going to more than 170 countries around the world. In the 2017 fiscal year, AbbVie reported $30.95 billion in sales with revenue per share at $19.49. They showed positive quarterly revenue growth at 19.2 percent and a small amount of quarterly earnings growth at 3.6 percent.